Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
作者信息
Müller-Thomas Catharina, Rudelius Martina, Rondak Ina-Christine, Haferlach Torsten, Schanz Julie, Huberle Christina, Schmidt Burkhard, Blaser Rainer, Kremer Marcus, Peschel Christian, Germing Ulrich, Platzbecker Uwe, Götze Katharina
机构信息
III. Department of Medicine, Technical University of Munich, Munich.
Institute of Pathology, Julius-Maximilians-University Würzburg, Munich.
出版信息
Haematologica. 2014 Oct;99(10):e179-81. doi: 10.3324/haematol.2014.104760. Epub 2014 Jun 27.
Abstract
摘要
相似文献
1
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.高危骨髓增生异常综合征和继发性急性髓系白血病中对阿扎胞苷的反应与p53表达无关。
Haematologica. 2014 Oct;99(10):e179-81. doi: 10.3324/haematol.2014.104760. Epub 2014 Jun 27.
2
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.TP53 基因突变在接受阿扎胞苷治疗的骨髓增生异常综合征和急性髓系白血病中的预后价值。
Leuk Res. 2014 Jul;38(7):751-5. doi: 10.1016/j.leukres.2014.03.012. Epub 2014 Mar 23.
3
Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.急性髓系白血病或骨髓增生异常综合征移植后复发患者接受阿扎胞苷治疗期间系列骨髓样本的突变分析。
Haematologica. 2017 Jun;102(6):e216-e218. doi: 10.3324/haematol.2016.162909. Epub 2017 Feb 16.
4
Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.糖原合成酶1（GYS1）、巨噬细胞移动抑制因子（MIF）和原癌基因（MYC）的过表达与骨髓增生异常综合征和急性髓系白血病的不良预后及对阿扎胞苷反应不佳相关。
Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):236-44. doi: 10.1016/j.clml.2014.10.003. Epub 2014 Oct 23.
5
Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.在“现实生活”环境中，5-氮杂胞苷治疗可改善高危骨髓增生异常综合征患者的临床结局：一项单中心观察性研究。
Hematology. 2016 Jan;21(1):34-41. doi: 10.1179/1607845415Y.0000000039. Epub 2015 Jul 28.
6
Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy.接受基于阿扎胞苷治疗的急性髓系白血病和高危骨髓增生异常综合征患者中单次打击和多次打击TP53改变的预后意义。
Leukemia. 2023 Jan;37(1):240-243. doi: 10.1038/s41375-022-01766-z. Epub 2022 Nov 27.
7
Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.阿扎胞苷治疗相关性骨髓增生异常综合征和急性髓系白血病中的克隆选择。
Eur J Haematol. 2020 May;104(5):488-498. doi: 10.1111/ejh.13390. Epub 2020 Mar 9.
8
Azacitidine effectively reduces -mutant leukemic cell burden in secondary acute myeloid leukemia after cord blood transplantation.阿扎胞苷可有效降低脐血移植后继发性急性髓系白血病中的 - 突变白血病细胞负荷。
Leuk Lymphoma. 2018 Nov;59(11):2755-2756. doi: 10.1080/10428194.2018.1443335. Epub 2018 Apr 12.
9
To target the untargetable: elucidation of synergy of APR-246 and azacitidine in mutant myelodysplastic syndromes and acute myeloid leukemia.靶向不可靶向之物：阐明APR-246与阿扎胞苷在突变型骨髓增生异常综合征和急性髓系白血病中的协同作用
Haematologica. 2020 Jun;105(6):1470-1472. doi: 10.3324/haematol.2020.249060.
10
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.阿扎胞苷与来那度胺序贯联合治疗伴有del(5q)的高危骨髓增生异常综合征或急性髓系白血病：一项I期研究。
Leukemia. 2013 Jun;27(6):1403-7. doi: 10.1038/leu.2013.26. Epub 2013 Jan 28.
引用本文的文献
1
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.从血液系统恶性肿瘤中p53的调控到去调控：对诊断、预后和治疗的影响
Biomark Res. 2024 Nov 14;12(1):137. doi: 10.1186/s40364-024-00676-9.
2
Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes.增强的 ALOX12 基因表达预测骨髓增生异常综合征患者对 5-氮杂胞苷治疗的敏感性。
Int J Mol Sci. 2024 Apr 23;25(9):4583. doi: 10.3390/ijms25094583.
3
Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine-A Retrospective Analysis.接受阿扎胞苷治疗的骨髓增生异常综合征患者的真实世界结局及预后因素——一项回顾性分析
Cancers (Basel). 2024 Mar 29;16(7):1333. doi: 10.3390/cancers16071333.
4
Drug Repurposing by Tumor Tissue Editing.通过肿瘤组织编辑实现药物重新利用。
Front Oncol. 2022 Jun 24;12:900985. doi: 10.3389/fonc.2022.900985. eCollection 2022.
5
Targeting -Mutated Acute Myeloid Leukemia: Research and Clinical Developments.靶向突变型急性髓系白血病：研究与临床进展
Onco Targets Ther. 2022 Apr 21;15:423-436. doi: 10.2147/OTT.S265637. eCollection 2022.
6
TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms.TP53突变使髓系肿瘤对低甲基化剂和BCL-2抑制产生耐药性。
Blood Adv. 2022 Jun 14;6(11):3201-3206. doi: 10.1182/bloodadvances.2021005859.
7
TP53 in Myelodysplastic Syndromes.骨髓增生异常综合征中的TP53
Cancers (Basel). 2021 Oct 27;13(21):5392. doi: 10.3390/cancers13215392.
8
Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality.与检测伴有5号染色体长臂缺失细胞遗传学异常的骨髓增生异常综合征患者的TP53体细胞突变相比，骨髓组织化学TP53表达的准确性。
Am J Blood Res. 2021 Aug 15;11(4):417-426. eCollection 2021.
9
in Myelodysplastic Syndromes: Recent Biological and Clinical Findings.在骨髓增生异常综合征：最新的生物学和临床发现。
Int J Mol Sci. 2020 May 13;21(10):3432. doi: 10.3390/ijms21103432.
10
Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study.5 天地西他滨与 7 天地阿扎胞苷治疗伴有不良预后特征的低危骨髓增生异常综合征的比较：一项回顾性多中心队列研究。
Sci Rep. 2020 Jan 8;10(1):39. doi: 10.1038/s41598-019-56642-1.
本文引用的文献
1
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).p53蛋白表达可独立预测伴有5号染色体长臂缺失（del(5q)）的低危骨髓增生异常综合征患者的预后。
Haematologica. 2014 Jun;99(6):1041-9. doi: 10.3324/haematol.2013.098103. Epub 2014 Mar 28.
2
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.944例骨髓增生异常综合征患者的基因损伤图谱
Leukemia. 2014 Feb;28(2):241-7. doi: 10.1038/leu.2013.336. Epub 2013 Nov 13.
3
Clinical and biological implications of driver mutations in myelodysplastic syndromes.骨髓增生异常综合征中驱动突变的临床和生物学意义。
Blood. 2013 Nov 21;122(22):3616-27; quiz 3699. doi: 10.1182/blood-2013-08-518886. Epub 2013 Sep 12.
4
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.阿扎胞苷与来那度胺序贯联合治疗伴有del(5q)的高危骨髓增生异常综合征或急性髓系白血病：一项I期研究。
Leukemia. 2013 Jun;27(6):1403-7. doi: 10.1038/leu.2013.26. Epub 2013 Jan 28.
5
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.骨髓增生异常综合征中的 TP53 突变与 5 号染色体异常密切相关，并与不良预后相关。
Br J Haematol. 2013 Mar;160(5):660-72. doi: 10.1111/bjh.12203. Epub 2013 Jan 9.
6
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.新的原发性骨髓增生异常综合征（MDS）和 MDS 衍生的少突细胞急性髓系白血病的综合细胞遗传学评分系统，源自国际数据库合并。
J Clin Oncol. 2012 Mar 10;30(8):820-9. doi: 10.1200/JCO.2011.35.6394. Epub 2012 Feb 13.
7
Clinical effect of point mutations in myelodysplastic syndromes.骨髓增生异常综合征点突变的临床疗效。
N Engl J Med. 2011 Jun 30;364(26):2496-506. doi: 10.1056/NEJMoa1013343.
8
Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.ASXL1 基因突变对骨髓增生异常综合征患者的预后意义。
J Clin Oncol. 2011 Jun 20;29(18):2499-506. doi: 10.1200/JCO.2010.33.4938. Epub 2011 May 16.
9
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.低危伴有 del(5q)的骨髓增生异常综合征中 TP53 突变可预测疾病进展。
J Clin Oncol. 2011 May 20;29(15):1971-9. doi: 10.1200/JCO.2010.31.8576. Epub 2011 Apr 25.
10
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.阿扎胞苷与传统治疗方案治疗高危骨髓增生异常综合征的疗效比较：一项随机、开放标签的III期研究。
Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21.
Zotero 插件